RetinalGenix Technologies Inc. financial data

Symbol
RTGN on OTC
Location
1450 North Mcdowell Boulevard, Suite 150, Petaluma, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 19, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity -102 % -2.11%
Return On Equity 278 % -7.23%
Return On Assets -11.7K % +89.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 18M shares +2.32%
Common Stock, Shares, Outstanding 17.9M shares +3.78%
Entity Public Float 15.5M USD +13.5%
Common Stock, Value, Issued 1.79K USD +0.51%
Weighted Average Number of Shares Outstanding, Basic 17.9M shares +3.42%
Weighted Average Number of Shares Outstanding, Diluted 17.9M shares +3.42%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 153K USD +12.7%
General and Administrative Expense 1.27M USD +58.7%
Costs and Expenses 21.7K USD
Net Income (Loss) Attributable to Parent -4.04M USD +0.12%
Earnings Per Share, Basic -0.23 USD/shares +8%
Earnings Per Share, Diluted -0.23 USD/shares -100%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 44 USD -98.8%
Assets, Current 86.9K USD +4443%
Property, Plant and Equipment, Net 106 USD -48.5%
Assets 87K USD +4007%
Accounts Payable, Current 340K USD
Liabilities 1.9M USD +6.83%
Retained Earnings (Accumulated Deficit) -13.9M USD -40.9%
Stockholders' Equity Attributable to Parent -1.81M USD -2.06%
Liabilities and Equity 87K USD +4007%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -143K USD -84.2%
Net Cash Provided by (Used in) Financing Activities 193K USD +127%
Common Stock, Shares Authorized 80M shares 0%
Common Stock, Shares, Issued 17.9M shares +3.78%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 50.4K USD +578%
Depreciation 25 USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 1.65M USD +20.3%
Preferred Stock, Shares Authorized 40M shares 0%
Additional Paid in Capital 12.1M USD +49.4%
Deferred Tax Assets, Net of Valuation Allowance 3.32M USD +23.3%
Interest Expense 3.84K USD -17.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%